Article

Adolescent and young adult HPV vaccination in Australia: Achievements and challenges

Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.
Preventive Medicine (Impact Factor: 2.93). 10/2011; 53 Suppl 1:S29-35. DOI: 10.1016/j.ypmed.2011.08.015
Source: PubMed

ABSTRACT Australia commenced an ongoing school based government funded human papillomaviruses (HPV) (cervical cancer prevention) vaccination program in April 2007 for adolescent females aged 12-13 years. In addition, up to December 31, 2009, a catch-up program for young females 13-26 years of age was offered: a school-based vaccination program was used to offer HPV vaccine to girls enrolled in school (14-17 years), and general practitioners or other community health provider offered vaccine to young women aged 18-26 years. To date, only the quadrivalent vaccine (HPV 6/11/16/18) has been utilized in the funded program. Acceptance of the vaccine is high with coverage of 3 doses of the HPV vaccine in the school age cohort around 70%, and just over 30% in the older age cohort. Since the vaccination program was initiated, a reduction in new cases of genital warts of 73% among vaccine eligible age females has been evidenced in STI clinics across Australia. A reduction of 44% of new cases in young males (not a part of the free program) was also documented during this same time period, suggesting significant herd immunity. Similarly, in the state of Victoria, a small but significant decrease in high grade abnormalities in Pap screening findings has been reported in young women<18 years for the period 2007-9, as compared to pre-vaccination. Challenges for the future include how we can sustain and improve HPV vaccination coverage in young Australian women, while maintaining cervical cancer screening participation and reviewing cervical cancer screening methods.

Download full-text

Full-text

Available from: S. Rachel Skinner, Jan 02, 2014
0 Followers
 · 
129 Views
  • Source
    • "B. Gunasekaran et al. / Vaccine xxx (2014) xxx–xxx programme available to 13–26 year old women through general practice and community-based programmes [2]. Presently, there is an ongoing school-based vaccination programme providing the HPV vaccine free to all boys and girls aged 12 to 13 years, with a two year catch-up programme for 14–15 year old boys until the end of 2014 [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Australia was the first country to implement a government-funded National Human Papillomavirus (HPV) Vaccination Program. We assessed HPV vaccine knowledge, uptake (self-reported and Register validated) and attitudes of young women post-implementation of the program. Females, aged 16 to 25 years living in Victoria, Australia, were recruited using targeted advertising on Facebook from May-September 2010, to complete a web-based questionnaire. Geographic distribution, Indigenous and socio-economic status of the 278 participants were representative of the target population. Overall, 210/278 (76%) had heard of HPV vaccines, with 203 (97%) of them knowing that Pap smears were ongoing despite vaccination and 191 (92%) aware that Pap abnormalities may occur post-vaccination. While 162/278 (58%) reported receipt of at least one dose of vaccine, 54 (19%) were unsure. Verification of HPV vaccination status of 142 participants (51%) showed 71% had received at least one dose. Main reasons for vaccination were for protection against HPV infection and cervical cancer (96%) and because it was free (87%), whereas unvaccinated women were uncertain of their eligibility (50%), concerned about adverse reactions (32%), or perceived that vaccination was not needed if they were monogamous (32%). HPV vaccine knowledge among participants was relatively high suggesting the national program has successfully communicated to the majority of eligible women, the purpose and limitations of the vaccine. Vigilance is needed to ensure that young women follow through with Pap testing in vaccine eligible cohorts. The potential utility of a vaccination register in the context of a national program is apparent from the large proportion of young women who were unsure of their vaccine status. The ongoing vaccination program for pre-adolescent girls and boys should communicate to parents that those with one sexual partner can still acquire HPV and that the safety of the vaccine is now well demonstrated. Copyright © 2014. Published by Elsevier Ltd.
  • Source
    • "Please cite this article as: Zimet, G.D., et al., Beliefs, behaviors and HPV vaccine: Correcting the myths and the misinformation, Preventive Medicine (2013), http://dx.doi.org/10.1016/j.ypmed.2013.05.013 demonstrated by the high rates of vaccination achieved in Australia, the U.K., and Canada (Franceschi, 2010; Garland et al., 2011; Shearer, 2011). Another policy-based approach would be for insurance companies to establish practice guidelines with high rates of HPV vaccination identified as a benchmark for successful provision of health care. "
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: HPV vaccine uptake in many countries has been sub-optimal. We examine several issues associated with non-vaccination that have received particular attention, including fears about sexual risk-compensation, concerns about vaccine safety, inadequate vaccination recommendations by health care providers (HCPs), and distrust due to the perceived "newness" of HPV vaccines. METHODS: Selective review of behavioral and social science literature on HPV vaccine attitudes and uptake. RESULTS: There is no evidence of post-vaccination sexual risk-compensation, HPV vaccines are quite safe, and they can no longer be considered "new". Nonetheless, research findings point to these issues and, most importantly, to the failure of HCPs to adequately recommend HPV vaccine as major drivers of non-vaccination. CONCLUSION: Most fears related to HPV vaccine are more related to myth than reality. In the absence of major health policy initiatives, such as those implemented in Canada, the U.K., and Australia, a multi-level, multi-faceted approach will be required to achieve high rates of HPV vaccination. It will be essential to focus on the education of HCPs regarding indications for HPV vaccination and approaches to communicating most effectively with parents and patients about the safety and benefits of vaccination and the risks associated with non-vaccination.
    Preventive Medicine 05/2013; 57(5). DOI:10.1016/j.ypmed.2013.05.013 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund 2007 wurde die HPV- („human papilloma virus-“)Impfung in der Schweiz eingeführt und in der Stadt Zürich mittels einer Impfaktion des Schulärztlichen Dienstes 2008 allen Schülerinnen zwischen 11 und 16 Jahren gratis angeboten. Danach impft der Schulärztliche Dienst im Rahmen einer Schulärztlichen Untersuchung in der 6. Und 8. Klasse. Die HPV-Impfung ist in der Schweiz umstritten und wird nicht selten, v. a. von impfkritischen Eltern, als überflüssig kritisiert. Ziel Das Ziel der vorgestellten Studie war zu ermitteln, wie 13- bis 15-jährige Schülerinnen die Entscheidung für oder gegen die Impfung treffen, und von welchen Akteuren sie in ihrer Entscheidungsfindung beeinflusst werden. Ergebnis Der größte Einflussfaktor bei der Entscheidung für oder gegen die Impfung sind die Eltern, insbesondere die Mütter der Schülerinnen. Diese sind ihrerseits von Frauen- und Kinderärzten beeinflusst. Die Medien, die Lehrpersonen sowie die Peers spielen eine eher untergeordnete Rolle. Insgesamt zeigen viele Akteure eine impfkritische Einstellung, die aber nur teilweise ausgesprochen wird. Um eine bessere Akzeptanz zu erreichen, müsste deshalb ein ganzheitlicher Entscheidungsprozess in den Schulen angestrebt werden, der alle Akteure mit einbezieht.
    Prävention und Gesundheitsförderung 02/2013; 8(1). DOI:10.1007/s11553-012-0372-z
Show more